LC
ADVM

Lindbrook Capital’s Adverum Biotechnologies ADVM Stock Holding History

Lindbrook Capital’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-41
Closed -$1K – 1840
2021
Q2 		$1K Buy
+41
New +$2.21K ﹤0.01% 1691
2020
Q4 		– Sell
-50
Closed -$5K – 1762
2020
Q3 		$5K Buy
+50
New +$7.49K ﹤0.01% 1082
2019
Q4 		– Sell
-300
Closed -$16K – 1493
2019
Q3 		$16K Buy
+300
New +$33.8K 0.01% 772

Other funds holding ADVM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lindbrook Capital's ADVM Position: Q3 2021 in Review

Lindbrook Capital sold out of Adverum Biotechnologies (ADVM) in Q3 2021, closing a stake of 41 shares — an estimated $1K sold.

Lindbrook Capital first reported a position in ADVM in Q3 2019 and held it in 3 quarters. The position peaked at $16K in Q3 2019. 110 funds tracked by Wall St. Rank hold ADVM as of Q3 2021.

  • Lindbrook Capital reported no remaining Adverum Biotechnologies position as of Q3 2021 after selling out during the quarter.
  • Lindbrook Capital sold 41 Adverum Biotechnologies shares in Q3 2021, an estimated $1K.
  • Lindbrook Capital first reported a position in Adverum Biotechnologies in Q3 2019 and held it in 3 quarters.
  • Lindbrook Capital's Adverum Biotechnologies position peaked at $16K in Q3 2019.
  • 110 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2021.

Based on Lindbrook Capital's 13F filing for Q3 2021, filed 5 Nov 2021.